Apotea AB (APOTEA) Fair Value & Analysis
Healthcare · SE · Market cap 7.8B SEK
Fair value as of: Jul 13, 2026
From 24 valuation models · updated 27 days ago
Share price −2.0% over the past month.
A solid business, but screening 40% overvalued on our models.
What matters now
- The model range is unusually wide (kr 26.49 to kr 124.81). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (20 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 13, 2026.
How to read this chart
20‑month range kr 55.15 – kr 120.20 · fair‑value band kr 26.49 – kr 124.81 · the kr 73.80 price screens above the kr 43.95 fair value. Dashed = 300-day average. As of Jul 13, 2026.
Analysis
Apotea AB (APOTEA) currently trades at kr 73.80, while our model-based Fair Value estimate is kr 43.95, implying the stock looks roughly 40.5% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Apotea AB generated revenue of 7.4B SEK at a net margin of 3.2%. Revenue grew 10.5% year over year. It earns a return on equity of 28.3%. Net debt stands at 328M SEK. Fundamentals as of Jul 13, 2026
Our scenario range runs from kr 26.49 (bear case) to kr 124.81 (bull case); at kr 73.80, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 39% below its 52-week high and 37% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -40%, APOTEA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (kr 102.10) versus Asset-Based (kr 5.43). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 54 · Market factors (momentum, volatility) 33
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements.
Full company description
Apotea AB (publ) operates an online pharmacy in Sweden. The company offers products in the areas of allergy, face, child and parent, bite and sting, preparedness, animal, fever and aches, cold, home and household, aid, hair removal and shaving, hair care, hands and feet, intimate, and dietary supplements. It also provides products in the categories of body care, stomach and intestine, food and drink, mouth and teeth, premium, trip, sex and lust, stop smoking, makeup, sun protection, wounds and injuries, sleep and sleep problems, training, weight control, vitamins and minerals, charity, and eyes and ears. In addition, the company offers services comprising leasing, leasing of personnel to related companies. and market contributions. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Apotea AB reported revenue of kr 7.2B in FY2025 versus kr 505M in FY2021, a compound +94.4%/yr. Reported net income was kr 229M in FY2025, compounding +110.9%/yr from FY2021.
APOTEA screens 40% overvalued. Compare with JD Health International Inc →
Peer Group
Pharmaceutical Retailers · 61 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc 6618 | HK$39.20 | HK$33.28 | -15% |
| Raia Drogasil S.A RADL3 | R$18.20 | R$15.58 | -14% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.24 | ¥29.07 | +44% |
| DaShenLin Pharmaceutical Group 603233 | ¥17.81 | ¥23.86 | +34% |
| Corporativo Fragua, S.A. FRAGUAB | 463.00 MXN | 821.18 MXN | +77% |
| LBX Pharmacy Chain Joint Stock Company 603883 | ¥11.51 | ¥10.57 | -8% |
| MedPlus Health Services Limited MEDPLUS | ₹690.20 | ₹379.25 | -45% |
| Yixintang Pharmaceutical Group 002727 | ¥11.46 | ¥9.45 | -18% |
| Anhui Huaren Health Pharmaceutical Co 301408 | ¥14.40 | ¥10.05 | -30% |
| ShuYu Civilian Pharmacy Corp 301017 | ¥13.34 | ¥5.91 | -56% |
Compare Apotea AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Apotea AB (APOTEA) overvalued or undervalued?
What is the fair value of APOTEA?
What is the quality score of APOTEA?
What is the revenue of Apotea AB (APOTEA)?
What is the net profit margin of APOTEA?
Does Apotea AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Apotea AB and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.